BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35364561)

  • 1. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
    Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
    Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Selected Flavonoid Derivatives as Potent FLT3 Inhibitors for the Potential Treatment of Acute Myeloid Leukemia.
    Yen SC; Chen LC; Huang HL; Ngo ST; Wu YW; Lin TE; Sung TY; Lien ST; Tseng HJ; Pan SL; Huang WJ; Hsu KC
    J Nat Prod; 2021 Jan; 84(1):1-10. PubMed ID: 33393294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines.
    Katayama K; Nishihata A
    Biol Pharm Bull; 2021 Dec; 44(12):1843-1850. PubMed ID: 34602526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.
    Yen SC; Chen LC; Huang HL; HuangFu WC; Chen YY; Eight Lin T; Lien ST; Tseng HJ; Sung TY; Hsieh JH; Huang WJ; Pan SL; Hsu KC
    Bioorg Chem; 2022 Apr; 121():105675. PubMed ID: 35182882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice.
    Naganna N; Opoku-Temeng C; Choi EY; Larocque E; Chang ET; Carter-Cooper BA; Wang M; Torregrosa-Allen SE; Elzey BD; Lapidus RG; Sintim HO
    EBioMedicine; 2019 Feb; 40():231-239. PubMed ID: 30686755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-(4-aminophenyl)-6-phenylisoxazolo[3,4-b]pyridine-3-amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia.
    Wang QX; Wang YB; Sha JK; Zhou H; Liu JC; Wu JZ; Tong ZJ; Cai J; Chen ZJ; Zhang CQ; Zheng XR; Wang JJ; Wang XL; Xue X; Yu YC; Ding N; Leng XJ; Dai WC; Sun SL; Chang L; Li NG; Shi ZH
    Drug Dev Res; 2023 Apr; 84(2):296-311. PubMed ID: 36644989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia.
    Teo T; Lam F; Yu M; Yang Y; Basnet SK; Albrecht H; Sykes MJ; Wang S
    Mol Pharmacol; 2015 Aug; 88(2):380-9. PubMed ID: 26044548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
    Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
    Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
    Heng H; Zhi Y; Yuan H; Wang Z; Li H; Wang S; Tian J; Liu H; Chen Y; Lu T; Ran T; Lu S
    Eur J Med Chem; 2019 Feb; 163():195-206. PubMed ID: 30508668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
    Tyagi A; Jaggupilli A; Ly S; Yuan B; El-Dana F; Hegde VL; Anand V; Kumar B; Puppala M; Yin Z; Wong STC; Mollard A; Vankayalapati H; Foulks JM; Warner SL; Daver N; Borthakur G; Battula VL
    Leukemia; 2024 Jan; 38(1):82-95. PubMed ID: 38007585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia.
    Xu B; Zhao Y; Wang X; Gong P; Ge W
    Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
    Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
    Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of a Potent and Selective FLT3 Inhibitor (
    Wang J; Pan X; Song Y; Liu J; Ma F; Wang P; Liu Y; Zhao L; Kang D; Hu L
    J Med Chem; 2021 Apr; 64(8):4870-4890. PubMed ID: 33797247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with
    Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H
    Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
    Lee JH; Shin JE; Kim W; Jeong P; Kim MJ; Oh SJ; Lee HJ; Park HW; Han SY; Kim YC
    Eur J Med Chem; 2022 Jul; 237():114356. PubMed ID: 35489222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
    Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.